BackKrystal Biotech Overview

Krystal Biotech Long Term Debt

Track Krystal Biotech's long-term debt ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00
↓ 100.00% YoYΔ $-8.30M vs prior year quarter

Peer average

Loading

Krystal Biotech Long Term Debt History

Loading

Krystal Biotech vs. peers: Long Term Debt Comparison

Loading

Krystal Biotech Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Krystal Biotech (KRYS) FAQ

Krystal Biotech (KRYS) currently reports a long-term debt of $0 as of March 2026. That compares with $8.3M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Krystal Biotech's long-term debt history and peer comparisons.

Krystal Biotech's long-term debt decreased from $8.3M to $0 — a 100.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Krystal Biotech reported $0 in long-term debt as of March 2026. That compares with $8.3M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Krystal Biotech, and consider following KRYS for alerts when major investors trade the stock.

Krystal Biotech is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KRYS with unrelated industries.